Newman James W. Jr.'s Form 4 filing
Adial Pharmaceuticals, Inc. (ADIL) · filed Jan 3, 2022
- Accession no.
- 0001213900-22-000067
- Filed
- Jan 3, 2022
- Trade date
- Dec 30, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $67.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Newman James W. Jr.CIK 0001718364 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2021 | Common Stock | PPurchaseAcquired | +10,000 | $2.66F1 | +$26,600 | 20,000 | Direct | |
| Dec 30, 2021 | Common Stock | PPurchaseAcquired | +5,000 | $2.72 | +$13,600 | 50,221 | Indirect | |
| Dec 30, 2021 | Common Stock | PPurchaseAcquired | +10,000 | $2.71F6 | +$27,100 | 34,644 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.628 to $2.68, inclusive. The reporting person undertakes to provide Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (6) of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.655 to $2.72, inclusive.
Referenced by the price of 1 transaction in Table I.